Ofev (Nintedanib Esylate) Patent Expiration, LOE Window & CMS Spending
Ofev (Nintedanib Esylate) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2026-04-01 (last listed 2029-12-07), 9 AB generics, $2.20B 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N205832 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2026-04-01 |
| Last Listed Patent or Exclusivity Date | 2029-12-07 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 9 |
| 2024 CMS Total Public Spend | $2.20B |
| 2024 Medicare Part D Spend | $2.09B |
| 2024 Medicaid Spend | $114.1M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 19.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.